Third-Party Tested ≥98% HPLC Purity — USA Shipped

Mitochondrial & Energy Research Guide

SS-31: Mechanism, Handling & Research Guide

Also known as: SS-31, Elamipretide, Bendavia, MTP-131, D-Arg-Dmt-Lys-Phe-NH2, SS-31 peptide

Key Facts

SS-31 is a mitochondrial & energy research peptide (C32H49N9O5, MW 639.8 g/mol). Cell-permeable peptide for mitochondrial function and cardiolipin stabilization research. It is supplied as a lyophilized powder for laboratory and in-vitro research use only — not for human consumption.

Classification Mitochondria-targeting (Szeto-Schiller) cationic tetrapeptide; cardiolipin-binding peptide
Molecular Formula C32H49N9O5
Molecular Weight 639.8 g/mol
CAS Number 736992-21-5
Research Half-Life Not well characterized; reported plasma half-life of approximately 2-4 hours in early pharmacokinetic work, qualifier-dependent on model and route
Form Lyophilized powder
Research Category Mitochondrial & Energy

What is SS-31?

SS-31, also known as Elamipretide or Bendavia (D-Arg-Dmt-Lys-Phe-NH2), is a cell-permeable tetrapeptide that selectively concentrates in the inner mitochondrial membrane. Its primary mechanism involves binding to cardiolipin, a phospholipid unique to mitochondrial membranes that is essential for electron transport chain organization and ATP synthase function. By stabilizing cardiolipin microdomains, SS-31 modulates electron transfer between complexes III and IV, reduces electron leak, and limits reactive oxygen species (ROS) generation at the source. Research by Szeto (2006) published in AAPS Journal described SS-31's unique mitochondria-targeting pharmacology, demonstrating 5,000-fold concentration in mitochondria relative to cytoplasm within minutes of exposure. Clinical studies published in Circulation: Heart Failure by Daubert et al. showed that SS-31 improved left ventricular volumes in heart failure patients during a Phase 1/2 trial. Preclinical work in the Journal of the American Society of Nephrology demonstrated renal protective effects in ischemia-reperfusion injury models, with SS-31 preserving mitochondrial cristae structure and reducing tubular cell death. Compared to general antioxidants like CoQ10 or vitamin E, SS-31 targets ROS production at the mitochondrial source rather than scavenging free radicals after they are formed. This upstream approach is considered more efficient by researchers. MitoQ, another mitochondria-targeted compound, accumulates via membrane potential rather than cardiolipin binding, giving SS-31 a distinct pharmacological profile, particularly in depolarized or damaged mitochondria. Store lyophilized SS-31 at -20°C in a desiccated, light-protected environment. Reconstitute with bacteriostatic water and store at 2-8°C, using within 4 weeks. SS-31 is actively investigated by mitochondrial biologists, cardiologists studying heart failure, nephrologists, and aging researchers examining mitochondrial dysfunction as a driver of age-related disease.

SS-31 Research Applications

In published and preclinical research, SS-31 has been studied across the following areas:

  • Mitochondrial function and ATP synthesis
  • Cardiovascular ischemia and heart failure
  • Glucose-metabolism and oxidative-stress research
  • Anti-inflammatory mechanisms

SS-31 in Research: Study Context

Published literature characterizes SS-31 (elamipretide) as a cell-permeable tetrapeptide that selectively concentrates at the inner mitochondrial membrane and binds cardiolipin, stabilizing electron-transport-chain organization and reducing reactive oxygen species at the source (Szeto 2014; Birk et al. 2013). Preclinical models report re-energization of ischemic mitochondria and preserved cristae structure, and a randomized placebo-controlled human trial reported tolerability and changes in left-ventricular volumes (Daubert et al. 2017). For laboratory research use only; SS-31 is not FDA-approved and no human concentration is provided. For in-vitro and laboratory study, the lyophilized peptide is reconstituted with bacteriostatic water to a defined concentration (e.g., 10 mg in 1 mL = 10 mg/mL) for benchtop preparation; design studies against the primary literature and document each lot's Certificate of Analysis (COA).

How SS-31 Compares

Researchers frequently evaluate SS-31 alongside related compounds:

  • SS-31 vs MOTS-c — Mitochondrial-derived peptide that acts via AMPK signaling and metabolic gene expression, contrasting SS-31's direct cardiolipin binding at the inner membrane.
  • SS-31 vs Epithalon — Tetrapeptide studied for telomerase/cellular-aging pathways rather than direct mitochondrial membrane stabilization, a different aging-research mechanism.

SS-31 — Frequently Asked Questions

What mechanism does the published SS-31 literature describe?
Primary literature describes SS-31 as concentrating in the inner mitochondrial membrane and binding cardiolipin, which stabilizes electron-transport-chain supercomplexes, reduces electron leak, and limits reactive-oxygen-species generation. Researchers characterize this as an upstream mechanism distinct from free-radical scavenging. These are in-vitro and preclinical findings only.
How is SS-31 prepared for in-vitro research?
For laboratory use, the lyophilized peptide is reconstituted with bacteriostatic water to a defined mg/mL stock (for example, 10 mg in 1 mL yields 10 mg/mL), added slowly along the vial wall without shaking. No human concentration is implied or provided - SS-31 is not FDA-approved and is for laboratory research use only. Confirm identity and purity against the lot COA before use.
How does SS-31 differ from MOTS-c in research models?
Literature describes distinct targets: SS-31 physically binds cardiolipin to stabilize the inner mitochondrial membrane directly, whereas MOTS-c is reported to act through AMPK signaling and metabolic gene expression. Researchers select between them based on whether the model probes acute mitochondrial membrane integrity or longer-term metabolic adaptation.
Is there human clinical literature on elamipretide?
Yes - a randomized, placebo-controlled trial (Daubert et al. 2017, Circulation: Heart Failure) reported that a single elamipretide infusion was tolerated and associated with changes in left-ventricular volumes. This is cited here only to characterize the published evidence base; the product is supplied for laboratory research use only and is not FDA-approved for any human use.
Is SS-31 legal to buy for research?
SS-31 is sold in the United States as a research chemical for laboratory and in-vitro use only. It is not approved by the FDA for human use and is not sold for human consumption. Researchers are responsible for compliance with all applicable federal, state, and institutional regulations.
Does SS-31 come with a Certificate of Analysis?
Yes. Every batch of SS-31 from Elyte Peptides ships with a third-party Certificate of Analysis (COA) documenting identity and HPLC purity (≥98%), so research results can be traced to a verified lot.
What is SS-31 (Elamipretide) and how does it work?
SS-31 (D-Arg-Dmt-Lys-Phe-NH2, also known as Elamipretide) is a cell-permeable tetrapeptide that selectively targets the inner mitochondrial membrane. It binds to cardiolipin, a phospholipid essential for electron transport chain complex organization and ATP synthesis. By stabilizing cardiolipin, SS-31 modulates mitochondrial cristae structure, reduces electron leak and ROS production, and modulates oxidative phosphorylation efficiency in preclinical models.
What research has been done on SS-31?
Research published in the Journal of the American Society of Nephrology demonstrated SS-31's renoprotective effects in ischemia-reperfusion models. Studies in Circulation showed improved cardiac function in heart failure models through restored mitochondrial efficiency. Phase 2/3 clinical trials (Stealth BioTherapeutics) investigated elamipretide for Barth syndrome and age-related mitochondrial dysfunction. Additional research has explored its neuroprotective and anti-diabetic potential.
How does SS-31 compare to MOTS-C for mitochondrial research?
SS-31 and MOTS-C target mitochondria through different mechanisms. SS-31 physically binds to cardiolipin on the inner mitochondrial membrane, directly stabilizing electron transport chain complexes. MOTS-C activates AMPK signaling to influence mitochondrial biogenesis and metabolic gene expression. SS-31 is more suited for acute mitochondrial rescue research, while MOTS-C addresses longer-term metabolic adaptation and mitochondrial turnover pathways.

Research References

  1. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014.
  2. Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013.
  3. Daubert MA, Yow E, Dunn G, et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circ Heart Fail. 2017.
All research guides